|  |
| --- |
| **Protocol Information** |
| **IRB #:**      **Title:**       |
| **Pharmacy Reviewer:**        |
| **[ ]  Initial Review** | **[ ]  Protocol Modification** | **[ ]  Investigator’s Brochure/Package Insert Update** |
|  |

|  |
| --- |
| **Summary of Pharmacy Observations for the Proposed Research:** |
|   |

|  |
| --- |
|  |
| **Directions:** When completing the sections below, if all suggested considerations are acceptable, check YES. Otherwise, indicate the items that are problematic. Describe the issue(s) in a comment box or in Requested Modifications at the end. |
| **Review Criteria 45 CFR 46.111(a) or 21 CFR 50.111(a)**  |
| [ ]  Yes | **Risks to subjects are minimized** |
| [ ]   | The objectives and hypotheses are not clearly stated |
| [ ]   | Pharmacokinetic/pharmacodynamic aspects of study design are not appropriate |
| [ ]   | Dose selection is not adequately justified based on Investigator’s Brochure and cited literature |
| [ ]   | Inclusion/exclusion criteria are not appropriate (including dosage form-specific criteria such as swallowing tablets whole, drug contraindications and FDA’s Special Alerts/Black Box Warnings) |
| [ ]   | All known important interactions are not addressed (e.g., drug-drug, drug-herb, drug-dietary supplement) |
| [ ]   | Laboratory monitoring plan is not adequate |
| [ ]   | Dose modifications for organ dysfunction are not included |
| [ ]   | Supportive care therapy is not adequately delineated or is not appropriate (e.g. pre-medications, hematopoietic growth factor support, infection prophylaxis). |
| [ ]   | Research will not contribute to Generalizable Knowledge and is not worth exposing subjects to risk. Include the following considerations: is the research feasible? |
| [ ]   | Alteration of study design, research procedures or subject population would reduce the likelihood of harm. |
| [ ]  Yes | **Informed Consent Document is appropriate** |
| [ ]  | FDA investigational or approval status is not clear |
| [ ]  | All common (>5%) and serious/life-threatening known risks are not included in the document |
| [ ]  | Risks of all pre-medications or other required supportive medications are not included if not standard of care |
| [ ]  | Prohibited concomitant medications (prescription and over-the-counter medications, herbal and dietary supplements, and food restrictions) are not adequately described  |
| [ ]  | Risks language is too technical (not lay language) |
| [ ]  | Cost to the subject, if any, are not adequately explained |

|  |
| --- |
| **FDA Regulated Drugs or Biologics Articles**  |
| [ ]  N/A | **Experimental Drugs and Biologics** (including approved drugs used outside their labeled indication) |
| [ ]  Yes [ ]  No | Is an IND required for the use of an experimental drug or biologic? |
| [ ]  Yes [ ]  No  | If “yes” has an IND application been submitted? **IND Number**:        |
| [ ]  Yes | **Investigational Drug/Biologic Information is sufficient and appropriate** |
| [ ]  | Adequate information regarding drug preparation, storage, and stability is not provided |
| [ ]  | Adequate information regarding special handling procedures is not provided |
| [ ]  | Adequate information for drug requisition and disposal is not provided |
| [ ]  Yes | **Non-Investigational Drug/Biologic Information is sufficient and appropriate** |
| [ ]  | Insufficient information was provided regarding the non-investigational drugs/biologics, including placebos to be administered during the research. Considerations should include: whether the drug is on Formulary and if not, the reputation of the source, quality, purity and stability of the drug.  |
| [ ]  | Compounding is required with non-USP source materials  |
| [ ]  | Inadequate information provided for compounding procedures.  |
|  |
| **Additional Information**  |

|  |
| --- |
|  |
|  |
| **Recommendations** |

|  |
| --- |
| **Pharmacy Recommendations** |
| [ ]  No Major issues[ ]  Minor modifications/Clarifications required that do not impact approval[ ]  Major modifications/clarifications required that impact one or more criteria for approval |
|  |
| **Pharmacy Reviewer Name/Signature:**        | **Date:**        |

|  |  |
| --- | --- |
| **Required Modifications** (if any) | **Addressed (Y/N)** |

|  |  |
| --- | --- |
| **eIRB Application** | [ ]  Yes [ ]  No [ ]  N/A |

|  |  |
| --- | --- |
|  |  |
|  |

|  |  |
| --- | --- |
| **Protocol:**  | [ ]  Yes [ ]  No [ ]  N/A |

|  |  |
| --- | --- |
|  |  |
|  |

|  |  |
| --- | --- |
| **Consent Form:**  | [ ]  Yes [ ]  No [ ]  N/A |

|  |  |
| --- | --- |
|  |  |
|  |

|  |  |
| --- | --- |
| **Other:**  | [ ]  Yes [ ]  No [ ]  N/A |

|  |  |
| --- | --- |
|  |  |
|  |

|  |
| --- |
| **Recommendations after Review of Modifications** |
| [ ]  All requested modifications/clarifications addressed[ ]  Additional modifications/clarifications required | **Stipulations to be reviewed by:**[ ]  Review by Chair or Designee       [ ]  Full Board Review |
| **Pharmacy Reviewer Signature:**        | **Date:**        |